middle.news
Independent Study Finds Mesoblast’s Remestemcel-L Outperforms Ruxolitinib in SR-aGvHD
10:22am on Friday 12th of December, 2025 AEDT
•
Healthcare
Read Story
Independent Study Finds Mesoblast’s Remestemcel-L Outperforms Ruxolitinib in SR-aGvHD
10:22am on Friday 12th of December, 2025 AEDT
Key Points
Meta-analysis of 2,732 patients across 11 studies
Remestemcel-L shows higher complete and overall remission rates
Favorable safety profile with fewer hematology, cardiac, and hepatic adverse events
Ryoncil is the first FDA-approved mesenchymal stromal cell therapy for pediatric SR-aGvHD
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
MSB
OPEN ARTICLE